Published in J Nat Sci on February 01, 2017
Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA (2003) 31.71
Global patterns of influenza a virus in wild birds. Science (2006) 13.80
Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet (2009) 3.97
The 2009 A (H1N1) influenza virus pandemic: A review. Vaccine (2010) 3.28
Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity. Science (2007) 2.95
Detection of prokaryotic mRNA signifies microbial viability and promotes immunity. Nature (2011) 2.93
Expression of antigenic determinants of the hemagglutinin gene of a human influenza virus in Escherichia coli. Proc Natl Acad Sci U S A (1981) 2.42
Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity. Nat Med (2005) 2.28
Expression of the influenza virus haemagglutinin in insect cells by a baculovirus vector. EMBO J (1986) 1.98
Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus. PLoS One (2010) 1.61
A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. PLoS One (2008) 1.57
Nasal vaccines. Adv Drug Deliv Rev (2001) 1.57
Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine (1998) 1.56
Commensals upon us. Biochem Pharmacol (2006) 1.49
Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs. PLoS One (2008) 1.44
Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J Infect Dis (2009) 1.27
Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity. J Infect Dis (2009) 1.17
Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virus. Vaccine (2009) 1.14
Immunological study of HA1 domain of hemagglutinin of influenza H5N1 virus. Biochem Biophys Res Commun (2009) 1.11
Comparing the antibody responses against recombinant hemagglutinin proteins of avian influenza A (H5N1) virus expressed in insect cells and bacteria. J Med Virol (2008) 1.10
Acid phosphatase: endpoint for in vitro toxicity tests. In Vitro Cell Dev Biol (1991) 1.10
Mucosal vaccines: novel advances in technology and delivery. Expert Rev Vaccines (2009) 1.09
Recommendations for the administration of influenza vaccine in children allergic to egg. BMJ (2009) 1.07
Glycan analysis in cell culture-based influenza vaccine production: influence of host cell line and virus strain on the glycosylation pattern of viral hemagglutinin. Vaccine (2009) 1.04
Use of MDCK cells for production of live attenuated influenza vaccine. Vaccine (2009) 1.02
Staphylococcus aureus hijacks a skin commensal to intensify its virulence: immunization targeting β-hemolysin and CAMP factor. J Invest Dermatol (2010) 1.01
Detection in 2009 of the swine origin influenza A (H1N1) virus by a subtyping microarray. J Clin Microbiol (2009) 1.00
Antibodies to a full-length VAR2CSA immunogen are broadly strain-transcendent but do not cross-inhibit different placental-type parasite isolates. PLoS One (2011) 1.00
An influenza A/H1N1/2009 hemagglutinin vaccine produced in Escherichia coli. PLoS One (2010) 0.97
NEW technologies for meeting the global demand for pandemic influenza vaccines. Biologicals (2008) 0.97
Specific recognition of influenza A/H1N1/2009 antibodies in human serum: a simple virus-free ELISA method. PLoS One (2010) 0.94
The essentiality of alpha-2-macroglobulin in human salivary innate immunity against new H1N1 swine origin influenza A virus. Proteomics (2010) 0.90
Topical application of Escherichia coli-vectored vaccine as a simple method for eliciting protective immunity. Infect Immun (2006) 0.89
Killed but metabolically active Salmonella typhimurium: application of a new technology to an old vector. J Infect Dis (2007) 0.88
Passive immunoprotection targeting a secreted CAMP factor of Propionibacterium acnes as a novel immunotherapeutic for acne vulgaris. Vaccine (2011) 0.87
Killed but metabolically active Bacillus anthracis vaccines induce broad and protective immunity against anthrax. Infect Immun (2009) 0.87
Synthesis of biologically active influenza virus hemagglutinin in insect larvae. J Virol (1989) 0.86
Vaccination targeting surface FomA of Fusobacterium nucleatum against bacterial co-aggregation: Implication for treatment of periodontal infection and halitosis. Vaccine (2010) 0.85
A novel vaccine targeting Fusobacterium nucleatum against abscesses and halitosis. Vaccine (2009) 0.81
Comparative analysis of hemagglutinin of 2009 H1N1 influenza A pandemic indicates its evolution to 1918 H1N1 pandemic. Gene (2011) 0.81
Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant. J Med Virol (2005) 0.79
Avian influenza in ovo vaccination with replication defective recombinant adenovirus in chickens: vaccine potency, antibody persistence, and maternal antibody transfer. Avian Dis (2011) 0.78
West Nile virus: reducing the risk. FDA Consum (2003) 0.78
Intranasal delivery to the brain. Nat Biotechnol (2011) 0.77
Strategies for the plant-based expression of dengue subunit vaccines. Biotechnol Appl Biochem (2010) 0.77
Re-formulating drugs and vaccines for intranasal delivery: maximum benefits for minimum risks? Drug Discov Today (2010) 0.75